Committed to transforming
the treatment of severe, chronic
autoimmune diseases.

News

2022-01-13

Imcyse Reports Positive Immune Response from Interim Analysis of Phase 2 IMPACT Type 1 Diabetes Study

2021-11-03

Imcyse Appoints Gene Mack, MBA as Chief Financial Officer

2021-06-24

Imcyse appoints new Scientific Advisory Board and opens new laboratories for next phase of growth

2021-06-24

INNODIA is ready for a new phase – clinical trials

2021-02-17

Imcyse Raises Additional EUR 21.3 Million in Series B Financing Round – Pfizer Joins as Newest Shareholder

Go Back